Sign Out
Oxaliplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.
Pulmonary Toxicity: Oxaliplatin for injection has been associated with pulmonary fibrosis (<1% of the study patients), which may be fatal. The combined incidence of cough and dyspnea was 7.4% (any grade) and 1% (grade 3) with no grade 4 events in the oxaliplatin (Zildox) plus infusional 5-FU/LV arm, compared to 4.5% (any grade) and no grade 3 and 0.1% grade 4 events in the infusional 5-FV/LV arm alone in adjuvant colon cancer patients.
Hepatotoxicity: Hepatotoxicity, as evidenced in adjuvant study by the increase in transaminases (57% vs 34%) and alkaline phosphatase (42% vs 20%), was observed more commonly in oxaliplatin combination arm.
